Ion; 2011.doi:ten.11861475-2875-12-450 Cite this article as: Quashie et
Ion; 2011.doi:ten.11861475-2875-12-450 Cite this article as: Quashie et al.: A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs. Malaria Journal 2013 12:450.Submit your next manuscript to BioMed Central and take full advantage of:Hassle-free on the net submission Thorough peer review No space constraints or color figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Analysis that is freely out there for CysLT1 Purity & Documentation redistributionSubmit your manuscript at biomedcentralsubmit
HIPPOKRATIA 2013, 17, 2:187-CASE REPORTBleomycin cardiotoxicity for the duration of chemotherapy for an ovarian germ cell tumorDidagelos M, Boutis A, Diamantopoulos N, Sotiriadou M, Fotiou C1st Department of Clinical BACE1 Formulation Oncology-Chemotherapy, Theagenio Cancer Hospital, Thessaloniki, GreeceAbstract Introduction: Platinum-based chemotherapeutic regimens, such as BEP (bleomycin, etoposide, cisplatin) represent the regular of care, first line therapy in non-epithelial ovarian tumours. Cardiovascular toxicity is often a uncommon adverse impact of bleomycin. Case Report: A 41-year-old lady with ovarian granulosa tumor, treated with initially line BEP chemotherapy knowledgeable chest discomfort quickly progressing to serious precordial pain in the course of bleomycin infusion. The infusion was stopped and electrocardiographic modifications indicative of myocardial ischemia have been revealed. Anti-anginal and anti-thrombotic remedy was introduced. Cardiac enzymes weren’t elevated and echocardiographic findings showed no wall motion abnormalities. Twenty 4 hours following the episode the elctrocardiographic adjustments insisted and chemotherapy was decided to be continued, excluding bleomycin, with no symptom recurrence. Discussion: Cardiovascular complications pose a rare but prospective fatal adverse impact of BEP chemotherapy and ought to be very carefully addressed, in particular in patients with extra cardiovascular threat things. Physicians coping with bleomycin-based therapies could obtain this understanding helpful for any far more extensive evaluation of chest discomfort syndromes in these patients. Hippokratia 2013, 17, two: 1787-188 Keyword phrases: BEP chemotherapy, ovarian cancer, cardiotoxicity, myocardial ischemia, chest painCorresponding Author: Anastasios Boutis, 1st Division of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, 54007, Thessaloniki, Greece, tel.: 302310898711, 306937040299, fax:302310845514, e-mail: alboutisotenet.grIntroduction BEP (bleomycin, etoposide, cisplatin) chemotherapeutic regimen represents the standard of care first line therapy in non-epithelial ovarian tumours1. Cardiovascular toxicity can be a uncommon adverse effect of bleomycin and might be expressed clinically as hypotension, pericarditis, acute substernal chest pain, coronary artery disease, myocardial ischemia, myocardial infarction, cerebral vascular accident and Raynaud’s phenomenon2. Case report A 41-year-old lady with advanced recurrent ovarian cancer (adult granulosa cell tumor, initial stage pT2b pN1 M0, FIGO IIIC, four years before) was treated with initial line platinum-based chemotherapy. Pre-treatment cardiovascular threat components included arterial hypertension (nicely controlled with angiotensin II receptor blockers) and obesity (BMI: 40.three Kgm2). Baseline cardiologic evaluation with ECG and echocardiogram just prior to initiation of chemotherapy was unremarkable. In the course of the very first cycle of therapy and in the course of the bleomycin infusion, ch.
